STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more

Merck intends to buy Terns Pharmaceuticals, the developer of a promising leukemia treatment, for $6.7 billion
Source
Stat News
Opens original article in a new tab



